We speculate a novel limotherapy for treating cancers that disturbs the relationship of metabolic symbiosis by controlling the MCT4 expression and/or specifically blocking the MCT1 expression, the possible mechanisms including lactate shuttles, immune suppression, oxidative stress, and neovascularization. This evidence concerns the gene SLC16A1 and cancer.